ImmunityBio Shares Surge on Stellar ANKTIVA Performance and Revenue Forecast
Published on 02/25/2026 at 09:52 | Redaktion boerse-global.de
ImmunityBio has announced a dramatic surge in projected revenue for 2025, driven by the explosive performance of its immunotherapy drug, ANKTIVA. The biotechnology firm reported preliminary 2025 revenue of approximately $113 million on February 23, representing a staggering 700% increase over the prior year. This growth is attributed to a sevenfold expansion in the drug's sales volume.
International Expansion and Quarterly Results
The revenue leap coincides with ANKTIVA's broadening global reach. Following recent approvals from both the European Commission and Saudi Arabia's drug authority, the treatment is now authorized for use in 33 countries.
Financially, the company reported $38.29 million in revenue for the fourth quarter alone. Its loss per share came in at $0.06, which was narrower than the anticipated $0.08 loss. ImmunityBio's stock closed at $11.55 on February 24, giving the company a market capitalization of $9.68 billion.
Analyst Upgrades and Insider Transactions
Market analysts swiftly revised their outlooks following the announcement. H.C. Wainwright established a price target of $15 per share, while D. Boral Capital set a more bullish target of $23. The current analyst consensus rating stands at "Moderate Buy," with an average price target of $12.60.
Should investors sell immediately? Or is it worth buying ImmunityBio?
Alongside this positive business development, two board members executed share sales on February 23. Director Christobel Selecky sold 25,000 shares at $10 each, and Director Barry J. Simon divested 165,000 shares.
Ad
ImmunityBio Stock: New Analysis - 25 February
Fresh ImmunityBio information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
